Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report

Muhannad A Alsemari; Hakeam A Hakeam; Hussain Alsalman; Tarek Amin

doi:10.1177/2049936120952605

Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report

Ther Adv Infect Dis. 2020 Aug 26:7:2049936120952605. doi: 10.1177/2049936120952605. eCollection 2020 Jan-Dec.

Authors

Muhannad A Alsemari¹, Hakeam A Hakeam², Hussain Alsalman³, Tarek Amin⁴

Affiliations

¹ Department of Surgery, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
² Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
³ Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
⁴ Hepatobiliary and Surgical Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

Abstract

High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who developed reversible cutaneous hyperpigmentation within 48 h of receiving high-dose tigecycline.

Keywords: adverse effect; high dose; hyperpigmentation; tigecycline.

Publication types

Case Reports